ARVN

Arvinas

• NASDAQ·04/02 06:55

  Arvinas (ARVN) Moves 6.9% Higher: Will This Strength Last?

• TipRanks·03/20 02:06

  Top Executive’s Surprise Stock Move Shakes Up Arvinas Holding Company

• Dow Jones·03/19 15:39

  Arvinas Is Maintained at Buy by Citigroup

• Dow Jones·03/19 15:39

  Arvinas Price Target Raised to $21.00/Share From $18.00 by Citigroup

• Benzinga·03/19 15:29

  Citigroup Maintains Buy on Arvinas, Raises Price Target to $21

• Dow Jones·03/19 13:01

  Arvinas Price Target Raised to $16.00/Share From $14.00 by BTIG

• Dow Jones·03/19 13:01

  Arvinas Is Maintained at Buy by BTIG

• Benzinga·03/19 12:51

  BTIG Maintains Buy on Arvinas, Raises Price Target to $16

• TipRanks·03/19 12:30

  Analysts’ Opinions Are Mixed on These Healthcare Stocks: Gossamer Bio (GOSS), High Tide (HITI) and Arvinas Holding Company (ARVN)

• TipRanks·03/19 12:05

  Arvinas Buy Rating Driven by Robust ARV-102 LRRK2 Degrader Data and Clear Neurodegeneration Development Path

• TipRanks·03/19 11:17

  Analysts Have Conflicting Sentiments on These Healthcare Companies: ProKidney (PROK), HeartFlow, Inc. (HTFL) and Arvinas Holding Company (ARVN)

• TipRanks·03/19 11:13

  Wells Fargo Reaffirms Their Buy Rating on Arvinas Holding Company (ARVN)

• TipRanks·03/19 10:45

  Balanced View on Arvinas: Early Promise of ARV-102 Offset by Clinical, Safety, and Competitive Uncertainties Supporting a Hold Rating

• TipRanks·03/19 10:10

  Analysts Offer Insights on Healthcare Companies: Arvinas Holding Company (ARVN), HOYA (OtherHOCPF) and TransMedics Group (TMDX)

• TipRanks·03/18 20:05

  ARV-102 Data Strengthens Neurodegeneration Pipeline Prospects, Supporting Higher $16 Target and Buy Rating on Arvinas